Drug Channels Institute (DCI) has published its latest exclusive analysis of the 340B contract pharmacy market, which continues to boom along with the overall program’s expansion. However, the 2026 analysis finds that the contract pharmacy market is now entering a more mature phase characterized by consolidation, slower growth, and increasing dominance by the industry’s largest participants. Nearly two-thirds of the entire U.S. pharmacy industry participates as contract pharmacies for the 340B hospitals and federal grantees. The number of 340B pharmacy locations declined for the third year, due largely to the retail pharmacy shakeout and manufacturers’ 340B policies.
Read the full article: The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs //
Source: https://www.drugchannels.net/2026/06/the-340b-contract-pharmacy-market-in.html